New hope for myelofibrosis patients: combo pill targets stubborn spleen swelling
NCT ID NCT06909136
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 31 times
Summary
This study tests whether adding a new drug (WJ01024) to the standard drug ruxolitinib can help people with myelofibrosis who have an enlarged spleen and didn't get better with previous treatments. About 33 adults with medium- to high-risk disease will take the combination and be monitored for safety, spleen shrinkage, and symptom relief. The goal is to control the disease and improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital
Zhengzhou, Zhengzhou, 450000, China
Conditions
Explore the condition pages connected to this study.